AGL vs. VRCI, GENI, ABDX, PRM, LLAI, DXRX, IUG, RENX, NCYT, and AREC
Should you be buying ANGLE stock or one of its competitors? The main competitors of ANGLE include Verici Dx (VRCI), GENinCode (GENI), Abingdon Health (ABDX), Proteome Sciences (PRM), LungLife AI (LLAI), Diaceutics (DXRX), Intelligent Ultrasound Group (IUG), Renalytix (RENX), Novacyt (NCYT), and Arecor Therapeutics (AREC). These companies are all part of the "medical" sector.
Verici Dx (LON:VRCI) and ANGLE (LON:AGL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, community ranking, risk, media sentiment, profitability, valuation and institutional ownership.
Verici Dx's return on equity of -69.68% beat ANGLE's return on equity.
ANGLE received 181 more outperform votes than Verici Dx when rated by MarketBeat users.
Verici Dx has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500. Comparatively, ANGLE has a beta of 0.2, meaning that its stock price is 80% less volatile than the S&P 500.
In the previous week, Verici Dx and Verici Dx both had 1 articles in the media. Verici Dx's average media sentiment score of 0.00 beat ANGLE's score of -1.27 indicating that ANGLE is being referred to more favorably in the news media.
ANGLE has a consensus price target of GBX 70, indicating a potential upside of 351.61%. Given Verici Dx's higher probable upside, analysts plainly believe ANGLE is more favorable than Verici Dx.
Verici Dx has higher earnings, but lower revenue than ANGLE. ANGLE is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks.
47.3% of Verici Dx shares are held by institutional investors. Comparatively, 27.5% of ANGLE shares are held by institutional investors. 17.0% of Verici Dx shares are held by company insiders. Comparatively, 10.7% of ANGLE shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
ANGLE beats Verici Dx on 7 of the 13 factors compared between the two stocks.
Get ANGLE News Delivered to You Automatically
Sign up to receive the latest news and ratings for AGL and its competitors with MarketBeat's FREE daily newsletter.
Related Companies and Tools